Bridge City Capital LLC Has $6.31 Million Stake in Amphastar Pharmaceuticals, Inc. $AMPH

Bridge City Capital LLC raised its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 72.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 235,485 shares of the company’s stock after buying an additional 99,227 shares during the quarter. Amphastar Pharmaceuticals accounts for about 1.9% of Bridge City Capital LLC’s portfolio, making the stock its 11th largest position. Bridge City Capital LLC’s holdings in Amphastar Pharmaceuticals were worth $6,306,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Marshall Wace LLP lifted its stake in Amphastar Pharmaceuticals by 41.6% in the fourth quarter. Marshall Wace LLP now owns 1,237,284 shares of the company’s stock valued at $33,134,000 after buying an additional 363,216 shares during the period. Corient IA LLC acquired a new position in Amphastar Pharmaceuticals in the fourth quarter valued at about $201,000. Rafferty Asset Management LLC acquired a new stake in shares of Amphastar Pharmaceuticals during the fourth quarter worth about $206,000. State Street Corp raised its position in shares of Amphastar Pharmaceuticals by 2.1% during the fourth quarter. State Street Corp now owns 1,531,786 shares of the company’s stock worth $41,021,000 after purchasing an additional 31,044 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Amphastar Pharmaceuticals by 1.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 55,232 shares of the company’s stock worth $1,479,000 after purchasing an additional 897 shares during the period. Institutional investors and hedge funds own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Stock Down 2.1%

NASDAQ:AMPH opened at $20.09 on Friday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 2.82 and a current ratio of 3.85. The company has a market cap of $885.83 million, a PE ratio of 12.10, a PEG ratio of 3.95 and a beta of 0.91. Amphastar Pharmaceuticals, Inc. has a 52-week low of $16.65 and a 52-week high of $31.26. The stock has a 50-day simple moving average of $20.08 and a 200 day simple moving average of $23.39.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.42 earnings per share for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.28). The company had revenue of $171.17 million during the quarter, compared to the consensus estimate of $173.46 million. Amphastar Pharmaceuticals had a net margin of 11.00% and a return on equity of 15.12%. On average, sell-side analysts expect that Amphastar Pharmaceuticals, Inc. will post 2.41 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on AMPH. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $19.00 price target (down from $30.00) on shares of Amphastar Pharmaceuticals in a research report on Thursday, May 14th. Barclays dropped their price target on Amphastar Pharmaceuticals from $23.00 to $20.00 and set an “equal weight” rating on the stock in a research report on Wednesday, June 3rd. Weiss Ratings lowered Amphastar Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, April 10th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Friday, May 8th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $22.00 price target (down from $30.00) on shares of Amphastar Pharmaceuticals in a research report on Tuesday, April 21st. Seven research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce” and an average price target of $24.00.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.